Digital breast tomosynthesis plus mammography provides a 40 percent reduction in patient recalls, reducing anxiety and potentially cutting cost and overall radiation dose.
Digital breast tomosynthesis plus mammography screening provides a 40 percent reduction in patient recalls, say researchers from Yale University School of Medicine in New Haven. The results of their study were presented at the American Roentgen Ray Society Annual Meeting in Vancouver, Canada.
Recalls can be very stressful for the women, and the recall rate following traditional 2-D mammography alone is 11.1 percent, researchers said. To evaluate if recalls were fewer when combining screening, researchers compared that rate with the rate for women who underwent both a mammogram and digital breast tomosynthesis.
The recall rate following both a mammogram and digital tomosynthesis was only 6.6 percent, researchers found.
When women had masses, the recall rate was similar, but the recall rate was significantly lower when women had the screenings together, compared to mammography alone, for asymmetries (2.8 percent versus 7.1 percent, respectively) and calcifications, said Melissa Durand, MD, one of the study authors.
Liane Philpotts, MD, another study author, explains why: “Tomosynthesis, which is 3D mammography, allows us to look at the tissue in 1 mm slices. In routine mammography, breast tissue is compressed and overlying tissue can look like a suspicious finding. Tomosynthesis resolves this by looking slice by slice.”
The radiation dose for the two exams is below both the dose of film mammography and the FDA limit for mammography. The goal is to be able to get all the required information from just the tomosynthesis, eliminating the need for the 2-D mammogram, researchers said.
Not only do fewer recalls reduce the anxiety caused for the women involved, researchers said, but they also provide a cost savings and may reduce the overall screening radiation doses.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.